Entrada Therapeutics (TRDA) EBIAT: 2022-2025
Historic EBIAT for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to -$44.1 million.
- Entrada Therapeutics' EBIAT fell 214.52% to -$44.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.5 million, marking a year-over-year decrease of 288.27%. This contributed to the annual value of $65.6 million for FY2024, which is 1081.69% up from last year.
- Latest data reveals that Entrada Therapeutics reported EBIAT of -$44.1 million as of Q3 2025, which was down 2.39% from -$43.1 million recorded in Q2 2025.
- Over the past 5 years, Entrada Therapeutics' EBIAT peaked at $55.0 million during Q2 2024, and registered a low of -$44.1 million during Q3 2025.
- In the last 3 years, Entrada Therapeutics' EBIAT had a median value of -$9.5 million in 2023 and averaged -$4.1 million.
- Per our database at Business Quant, Entrada Therapeutics' EBIAT skyrocketed by 452.05% in 2024 and then crashed by 214.52% in 2025.
- Quarterly analysis of 4 years shows Entrada Therapeutics' EBIAT stood at -$24.6 million in 2022, then skyrocketed by 61.25% to -$9.5 million in 2023, then spiked by 111.85% to $1.1 million in 2024, then plummeted by 214.52% to -$44.1 million in 2025.
- Its EBIAT stands at -$44.1 million for Q3 2025, versus -$43.1 million for Q2 2025 and -$17.3 million for Q1 2025.